Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which Instax Camera Would it be a good idea for you to Purchase? - 2Working out at the airport? Some fliers can already smell the sweat.
- 3NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- 4Exploring ways to reduce the impact of space junk on Earth
- 5Southern Californians, your health insurance costs could rise in 2026
- Are multiverses real? An astrophysicist explains why it depends on how you define ‘real’
- The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- Turkey’s intel chief lays out country’s vision for Middle East, world
- Tesla Stock Hasn’t Looked This Cheap in a While
- Bold Colors, Playful Shapes, Handmade Textures: This Mexico City Home Is 100% Joyful!
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- Avoid Slam: Exploring the Pickup Truck Transformation
- Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
